Publication Name	World Journal of Hepatology
Manuscript ID	98142
Country	China

Received	2024-06-18 19:02
Peer-Review Started	2024-06-18 19:02
To Make the First Decision
Return for Revision	2024-08-15 20:54
Revised	2024-08-28 17:43
Second Decision	2024-09-19 02:45
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-19 13:03
Articles in Press	2024-09-19 13:03
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-09-23 05:07
Typeset the Manuscript	2024-09-27 02:04
Publish the Manuscript Online	2024-10-21 07:03

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients
Manuscript Source	Invited Manuscript
All Author List	Wei-Hua Cao, Ya-Qin Zhang, Xin-Xin Li, Zi-Yu Zhang and Ming-Hui Li
ORCID	Author(s) ORCID Number Ming-Hui Li http://orcid.org/0000-0003-3233-5473
Funding Agency and Grant Number	Funding Agency Grant Number The National Key Research and Development Program 2022YFC2603500 and 2022YFC2603505 Beijing Municipal Health Commission High-Level Public Health Technical Personnel Construction Project Discipline leader-03-26 The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority XXZ0302 The Capital Health Research and Development of Special Public Health Project 2022-1-2172 Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support XMLX 202127
Corresponding Author	Ming-Hui Li, MD, PhD, Chief Doctor, Professor, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Key Words	Hepatitis B virus; Hepatocellular carcinoma; Immune checkpoint inhibitors; Peginterferon alpha; Systematic treatment
Core Tip	Hepatitis B virus (HBV) infection interacts with tumor microenvironment (TME) through a highly complex and intertwined signaling pathway, which results in a special TME in hepatocellular carcinoma (HCC). Due to changes in the TME, tumor cells can evade immune surveillance by inhibiting tumor-specific T cell function through CTLA-4 and programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1). Interferon, as an immune factor with rich biological activity, can improve the TME of HBV-HCC through various pathways. Currently, the systematic treatment of HCC has gradually come out of the dilemma. In addition to the continuous emergence of new multi-target anti-vascular tyrosine kinase inhibitor drugs, immune checkpoint inhibitors have opened up a new situation for the systematic treatment of HCC, and the disease characteristics of patients included in global clinical studies are different from those of Chinese patients. Therefore, whether a group of HCC patients with HBV background and poor prognosis in China can also benefit from immunotherapy is a widely concerned issue.
Publish Date	2024-10-21 07:03
Citation	<p>Cao WH, Zhang YQ, Li XX, Zhang ZY, Li MH. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. <i>World J Hepatol</i> 2024; 16(10): 1158-1168</p>
URL	https://www.wjgnet.com/1948-5182/full/v16/i10/1158.htm
DOI	https://dx.doi.org/10.4254/wjh.v16.i10.1158

Full Article (PDF)	WJH-16-1158-with-cover.pdf
Manuscript File	98142_Auto_Edited_034509.docx
Answering Reviewers	98142-answering-reviewers.pdf
Audio Core Tip	98142-audio.mp3
Conflict-of-Interest Disclosure Form	98142-conflict-of-interest-statement.pdf
Copyright License Agreement	98142-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	98142-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	98142-non-native-speakers.pdf
Peer-review Report	98142-peer-reviews.pdf
Scientific Misconduct Check	98142-scientific-misconduct-check.png
Scientific Editor Work List	98142-scientific-editor-work-list.pdf
CrossCheck Report	98142-crosscheck-report.pdf
CrossCheck Report	98142-crosscheck-report.png